Are you Shigeru Nakagaki?

Claim your profile

Publications (3)0 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: Gefitinib and erlotinib are commercially available epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) that are widely used for the treatment of non-small-cell lung cancer (NSCLC). Acute severe liver injury, although rare, has been observed in patients receiving these EGFR-TKIs. Some studies have reported that erlotinib treatment does not cause severe liver toxicity in patients with NSCLC who previously presented with severe liver injury during the course of gefitinib treatment. We retrospectively assessed the occurrence of liver toxicity in patients with NSCLC who were receiving erlotinib and had previously presented with severe gefitinib-induced liver injury.Severe liver injury occurred in only 1 of the 8 patients receiving erlotinib treatment. In this case, erlotinib was discontinued because of the onset of grade 3 skin rash and liver injury. After liver function was restored, erlotinib (100 mg) was administered at a lower dose; nonetheless, grade 4 liver injury occurred. Our findings suggest that it is necessary not only to explain the early symptoms of liver toxicity to patients who are receiving erlotinib treatment and have previously experienced gefitinib-induced severe liver injury but also to more closely monitor liver function.
    Gan to kagaku ryoho. Cancer & chemotherapy 07/2010; 37(7):1307-11.
  • [Show abstract] [Hide abstract]
    ABSTRACT: We retrospectively investigated the frequency and severity of adverse events in 124 patients with colorectal cancer who were treated by mFOLFOX6 regimen from August, 2005 to December, 2006. The incidences of grade 3/4 adverse events were; leucopenia 16%, neutropenia 40%, anemia 11%, thrombocytopenia 7%, febrile neutropenia 7%, nausea 3%, vomiting 2%, anorexia 2%, diarrhea 4%, fatigue 7%, and alopecia 0%. The incidences of all grades and grade 3/4 hypersensitivity reaction were 35% and 4%, and the median number of course when it firstly appeared was 6(range, 1-21). The incidences of all grade and grade 3 peripheral sensory neuropathy were 74% and 6%, and the median number of course when it firstly appeared 11(range, 6-16). The incidences of adverse events in this cohort were similar or lower than those reported in Western countries. Our investigation shows that mFOLFOX6 regimen is tolerable in clinical practice in Japan. The informed consent form was revised based on these results. The incidences of adverse events were renewed to provide useful information and improve self-care ability. The symptoms and the time to appearance of the hypersensitivity reaction and peripheral sensory neuropathy were added. We think it is important to provide the information based on the clinical practice.
    Gan to kagaku ryoho. Cancer & chemotherapy 10/2009; 36(10):1697-702.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To optimize the dosage regimen of vancomycin (VCM) a dose of >2 g/day may be recommended as a result of simulation with therapeutic drug monitoring (TDM) . However the safety of high‑dose VCM(>2 g/day)has not been validated. In this study we retro‑ spectively investigated the factors relevant to the use of high‑dose VCM and the assessment of predictability and safety of high‑dose VCM. The results of our case control analysis of a high‑dose group(>2 g/day)and normal‑dose group(≦2 g/day)revealed that the patients in the high‑dose group were younger in age than those of the normal‑dose group and that the renal function in the high‑dose group was better than that in the normal‑dose group. It was suggested that VCM clearance in the younger patients was larger than the other patients. No significant difference in the predictability or safety was found between the two groups. In conclusion administration of high‑dose VCM with TDM does not increase the risk of adverse events. Early TDM and optimization of the dosage regimen should be considered among younger patients who may need higher doses of VCM.